Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

New results with ivabradine

Kim Fox

Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK

Angina pectoris is a common manifestation of coronary artery disease (CAD) and there is a need to improve quality of life, by reducing associated symptoms, and prognosis, by preventing acute coronary events. Ivabradine is a new medication which lowers heart rate (HR) by selectively inhibiting the If current without other direct cardiovascular effects. The antianginal and anti-ischaemic properties of ivabradine in patients with stable angina have been well demonstrated by placebo-controlled trials. This review analyses the results of two recently reported trials. The ASSOCIATE study showed that ivabradine, at the commonly used dose of 7.5 mg bid in patients with stable angina pectoris, on top of atenolol 50 mg daily was associated with a significant increase in exercise test parameters. In the BEAUTIfUL trial in patients with stable CAD and left ventricular dysfunction, ivabradine significantly reduced the risk of coronary events, in patients with HR ≥70 b.p.m. Furthermore, a subgroup analysis of the placebo arm showed prospectively that patients with HR ≥70 b.p.m. are at higher risk of coronary events. Both trials showed that ivabradine was well tolerated and could be safely combined with other currently used cardiovascular agents.

Key Words: Coronary artery disease • Stable angina • Coronary events • Ivabradine • Myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.